- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Lumera Exhibits at Society for Biomolecular Sciences 13th Annual Conference & Exhibition
Society for Biomolecular Sciences (SBS) 13th Annual Conference & Exhibition
Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, announced today that Tom Mino, President and Chief Executive Officer, will speak on a panel at the 2007 Washington State Technology Summit entitled, "The World of Nanotechnology Opportunities" on April 12, 2007. The Summit is being held at the Meydenbauer Center in Bellevue, Washington.
The Washington State Technology Summit brings together the region's entrepreneurs, researchers, industry executives, government officials, civic leaders and economic development champions to collectively examine technology innovation and the growth of Washington's industries.
In other news, Lumera also announced that it will be exhibiting at the Society for Biomolecular Sciences (SBS) 13th Annual Conference & Exhibition. The exhibition is being held in Montreal, Canada from April 15th to 19th, 2007. SBS 2007 has a registration of over one thousand attendees, three days of scientific presentations, and over one hundred and eighty exhibitors. Lumera will be exhibiting the ProteomicProcessor™ Instrument system and NanoCapture™ Microarray products.
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Hélène F. Jaillet, 425-398-6546
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015